Antiphospholipid Syndrome in Obstetrics

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thrombocytopenia. Treatment with heparin, aspirin, or intravenous immunoglobulins decreased the fetal loss rate. Treatment regimens in human are very difficult to interpret. Evidence from two prospective studies supported treatment with heparin and aspirin to improve pregnancy outcome. The risk of preeclampsia and placental insufficiency was substantial and occurred in 50% of patients. The general failure rate of heparin/aspirin treatment is approximately 30%. In such cases intravenous immunoglobulin in combination with heparin and aspirin has been used to treat APLS.

[1]  R. Marlar,et al.  Antiphospholipid Antibodies in Predicting Adverse Pregnancy Outcome: A Prospective Study , 1994, Annals of Internal Medicine.

[2]  C. Bombardier,et al.  Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. , 1997, The New England journal of medicine.

[3]  R. Perricone,et al.  Normal fetal growth in women with antiphospholipid syndrome treated with high‐dose intravenous immunoglobulin (IVIG) , 1995, Prenatal diagnosis.

[4]  Y. Shoenfeld,et al.  The Effect of Intravenous γ-Globulin on the Induction of Experimental Antiphospholipid Syndrome , 1993 .

[5]  D. Balaban,et al.  Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. , 1992, American journal of obstetrics and gynecology.

[6]  C. Turan,et al.  Antiphospholipid Antibodies in Eclamptic Women , 1998, Gynecologic and Obstetric Investigation.

[7]  M. Lockshin,et al.  Pregnancy and antiphospholipid antibody , 2001, Hämostaseologie.

[8]  C. Gordon,et al.  Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome , 1998, Lupus.

[9]  C. Romanini,et al.  Pregnancy Outcome in Recurrent Spontaneous Abortion Associated with Antiphospholipid Antibodies: A Comparative Study of Intravenous Immunoglobulin Versus Prednisone Plus Low‐Dose Aspirin , 2001, American journal of reproductive immunology.

[10]  G. Hughes,et al.  A study of sixty pregnancies in patients with the antiphospholipid syndrome. , 1996, Clinical and experimental rheumatology.

[11]  A. Caruso,et al.  Antiphospholipid antibodies in obstetrics: new complexities and sites of action. , 1999, Human reproduction update.

[12]  A. Clark,et al.  Clinical uses of intravenous immunoglobulin in pregnancy. , 1999, Clinical obstetrics and gynecology.

[13]  R. Stricker,et al.  Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. , 2000, Fertility and sterility.

[14]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[15]  L. Chamley,et al.  Antiphospholipid antibodies in women having in-vitro fertilization. , 1996, Human reproduction.

[16]  M. Cullen,et al.  Recurrent adverse pregnancy outcome and antiphospholipid antibodies. , 1990, American journal of obstetrics and gynecology.

[17]  K. Yamada,et al.  Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody. , 1992, Human reproduction.

[18]  G. Hédelin,et al.  Antiphospholipid Antibodies and Preeclampsia: A Case‐Control Study , 2001, Obstetrics and gynecology.

[19]  Y. Shoenfeld,et al.  Induction and treatment of the antiphospholipid syndrome – lessons from animal models , 2001, European journal of clinical investigation.

[20]  N. Raine-Fenning,et al.  Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[21]  T. Mori,et al.  Expression of Phosphatidylserine‐Dependent Antigens on the Surface of Differentiating BeWo Human Choriocarcinoma Cells , 1995, American Journal of Reproductive Immunology.

[22]  Y. Shoenfeld,et al.  Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular-weight heparin. , 1993, American journal of obstetrics and gynecology.

[23]  C. Coulam.  Understanding the immunobiology of pregnancy and applying it to treatment of recurrent pregnancy loss. , 2000, Early pregnancy.

[24]  L. Heilmann,et al.  The Influence of Antiphospholipid Antibodies on the Pregnancy Outcome of Patients With Recurrent Spontaneous Abortion , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[25]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.

[26]  I. Scharrer,et al.  Criteria for the Diagnosis of Lupus Anticoagulants: An Update , 1995, Thrombosis and Haemostasis.

[27]  N. Pattison,et al.  Antiphospholipid Antibodies in Pregnancy , 1992, The Australian & New Zealand journal of obstetrics & gynaecology.

[28]  T. Byers,et al.  Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. , 1999, Obstetrics and gynecology.

[29]  H. Cohen,et al.  Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) , 1997, BMJ.

[30]  T. Porter,et al.  Antiphospholipid antibodies in women at risk for preeclampsia. , 2001, American journal of obstetrics and gynecology.

[31]  J. Piette,et al.  A study of 75 pregnancies in patients with antiphospholipid syndrome. , 2001, The Journal of rheumatology.

[32]  I. Walker.  Thrombophilia in pregnancy , 2000, Journal of clinical pathology.

[33]  J. Skull,et al.  Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. , 2000, Fertility and sterility.

[34]  T. Porter,et al.  Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. , 2001, The Journal of allergy and clinical immunology.

[35]  J. Spinnato,et al.  Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. , 1995, American journal of obstetrics and gynecology.

[36]  K. Granger,et al.  Review : Obstetric outcome in antiphospholipid syndrome , 1997 .

[37]  H. M. Cheng,et al.  Antiphospholipid antibodies, annexin V, and pregnancy loss. , 1997, The New England journal of medicine.

[38]  Y. Shoenfeld,et al.  The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome. , 1993, Clinical immunology and immunopathology.

[39]  R. Silver,et al.  Outcome of Treated Pregnancies in Women With Antiphospholipid Syndrome: An Update of the Utah Experience , 1992, Obstetrics and gynecology.

[40]  R. Abbate,et al.  Prevention of miscarriage in antiphospholipid syndrome. , 1992, Autoimmunity.

[41]  Y. El‐Sayed,et al.  A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. , 2000, American journal of obstetrics and gynecology.

[42]  J. Mcintyre,et al.  The evolution, evaluation and interpretation of antiphospholipid antibody assays , 1995 .

[43]  R. Perricone,et al.  Normal fetal growth in women with antiphospholipid syndrome treated with high‐dose intravenous immunoglobulin (IVIG) , 1995, Prenatal diagnosis.

[44]  N. Rote,et al.  Antiphospholipid Antibodies and Reproduction: The Antiphospholipid Antibody Syndrome , 1999, American journal of reproductive immunology.

[45]  R. Bick.  State-of-the-Art Review: Antiphospholipid Thrombosis Syndromes , 2001 .

[46]  Coulam Cb.  Understanding the immunobiology of pregnancy and applying it to treatment of recurrent pregnancy loss. , 2000 .

[47]  J. Craig,et al.  Recurrent Pregnancy Loss With Antiphospholipid Antibody: A Systematic Review of Therapeutic Trials , 2002, Obstetrics and gynecology.

[48]  G. Hughes,et al.  Antiphospholipid antibodies , 1994, Clinical Reviews in Allergy.

[49]  C. Coulam.  Immunotherapy for recurrent spontaneous abortion. , 1995, Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy.

[50]  J. D. Vries,et al.  Underlying disorders associated with severe early-onset preeclampsia. , 1995, American journal of obstetrics and gynecology.

[51]  B. Tartakovsky,et al.  Anti-cardiolipin antibodies induce pregnancy failure by impairing embryonic implantation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Greaves,et al.  Marked variation in antiphospholipid antibodies during pregnancy: relationships to pregnancy outcome. , 1999, Human reproduction.

[53]  E. Frenkel,et al.  Antiphospholipid-thrombosis syndromes. , 2003, Haemostasis.

[54]  A. Caruso,et al.  Poor pregnancy outcome and anticardiolipin antibodies. , 1994, Fetal diagnosis and therapy.

[55]  L. Regan,et al.  O-126. Pregnancy complications in women with recurrent miscarriage and antiphospholipid antibodies treated with aspirin and heparin , 1997 .

[56]  K. Granger,et al.  Obstetric outcome in antiphospholipid syndrome. , 1997, Lupus.

[57]  W. Kutteh,et al.  A Clinical Trial for the Treatment of Antiphospholipid Antibody‐Associated Recurrent Pregnancy Loss With Lower Dose Heparin and Aspirin , 1996, American journal of reproductive immunology.

[58]  J. Kopelman,et al.  The Association of Antiphospholipid Antibodies With Pregnancies Complicated by Fetal Growth Restriction , 1991, Obstetrics and gynecology.

[59]  E. Matsuura,et al.  beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. , 1996, Human reproduction.

[60]  N. Pattison,et al.  Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. , 2000, American journal of obstetrics and gynecology.

[61]  M. Mitchell,et al.  Action of anticardiolipin and antibodies to β2-glycoprotein-I on trophoblast proliferation as a mechanism for fetal death , 1998, The Lancet.

[62]  W. Matzner,et al.  Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. , 1994, The Journal of reproductive medicine.

[63]  K. Takakuwa,et al.  Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy , 1995, Obstetrics and gynecology.

[64]  R. Pauzner,et al.  Treatment of Patients With Antiphospholipid Antibodies During Pregnancy , 1992, American journal of reproductive immunology.

[65]  D. Vinatier,et al.  Antiphospholipid syndrome and recurrent miscarriages. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[66]  A. Gilman‐Sachs,et al.  Immunoglobulin G infusion treatment for women with recurrent spontaneous abortions and elevated CD56+ natural killer cells. , 2000, Early pregnancy.

[67]  W. Kutteh.  Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. , 1996, American journal of obstetrics and gynecology.

[68]  J. Kwak,et al.  Elevated Peripheral Blood Natural Killer Cells Are Effectively Downregulated by Immunoglobulin G Infusion in Women With Recurrent Spontaneous Abortions , 1996, American journal of reproductive immunology.